Janus Henderson Global Life Sciences Fund Q1 2026 Commentary (JFNAX)
Janus Henderson Investors·2026-06-24·via All Articles on Seeking Alpha
Summary
Janus Henderson Global Life Sciences Fund returned -3.72% and the MSCI World Health Care Index returned -4.60%.
Revolution Medicines led contributors during the quarter. The clinical-stage oncology company that targets “undruggable” cancers surged on takeover reports for as much as $30 billion.
An underweight to Merck & Co. was the leading detractor for the quarter.